Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for FOLD

Stock NameAmicus Therapeutics Inc
TickerFOLD(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03152W1099
LEI549300MRD1SMUTNBPQ53

Show aggregate FOLD holdings

News associated with FOLD

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up on Analyst Upgrade
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report)’s stock price gapped up prior to trading on Thursday after Needham & Company LLC upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $7.97, but opened at $8.48. Needham & Company LLC now has a $14.00 price target on […] - 2025-09-19 02:39:04
Amicus Therapeutics (FOLD) Shares Cross Above 200 DMA
In trading on Wednesday, shares of Amicus Therapeutics Inc (Symbol: FOLD) crossed above their 200 day moving average of $7.91, changing hands as high as $7.99 per share. Amicus Therapeutics Inc shares are currently trading off about 0.1% on the day. The chart below shows the o - 2025-09-03 12:43:43
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.22
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month […] - 2025-08-06 02:30:55
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Jefferies Financial Group Inc. bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 187,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,533,000. Other large investors have also recently made changes to […] - 2025-08-04 04:13:07
Envestnet Asset Management Inc. Trims Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Envestnet Asset Management Inc. lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 56.1% during the 1st quarter, Holdings Channel reports. The firm owned 186,555 shares of the biopharmaceutical company’s stock after selling 238,864 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Amicus Therapeutics were worth $1,522,000 as […] - 2025-08-01 04:22:53
KLP Kapitalforvaltning AS Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
KLP Kapitalforvaltning AS lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 13.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 42,200 shares of the biopharmaceutical company’s stock after selling 6,800 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Amicus Therapeutics were worth $344,000 as of its […] - 2025-07-31 04:18:47
New York State Common Retirement Fund Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
New York State Common Retirement Fund cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 72.8% in the 1st quarter, Holdings Channel.com reports. The firm owned 256,484 shares of the biopharmaceutical company’s stock after selling 686,630 shares during the quarter. New York State Common Retirement Fund’s holdings in Amicus Therapeutics were worth […] - 2025-07-24 04:42:44
Edgestream Partners L.P. Purchases Shares of 58,396 Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Edgestream Partners L.P. purchased a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the first quarter, HoldingsChannel.com reports. The firm purchased 58,396 shares of the biopharmaceutical company’s stock, valued at approximately $477,000. A number of other hedge funds also recently made changes to their positions in FOLD. Virtus Fund Advisers LLC acquired […] - 2025-07-20 05:26:52
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month […] - 2025-07-09 02:49:13
Vontobel Holding Ltd. Has $397,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Vontobel Holding Ltd. cut its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 3.5% during the first quarter, Holdings Channel reports. The institutional investor owned 48,683 shares of the biopharmaceutical company’s stock after selling 1,752 shares during the quarter. Vontobel Holding Ltd.’s holdings in Amicus Therapeutics were worth $397,000 as of […] - 2025-07-08 04:58:51
Diversified Trust Co Grows Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Diversified Trust Co grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 2.2% during the first quarter, Holdings Channel reports. The institutional investor owned 83,542 shares of the biopharmaceutical company’s stock after acquiring an additional 1,784 shares during the quarter. Diversified Trust Co’s holdings in Amicus Therapeutics were worth $682,000 as of […] - 2025-06-30 05:10:56
Amicus Therapeutics' Pombiliti+Opfolda Receives Japan MHLW's Approval For Pompe Treatment
(RTTNews) - Amicus Therapeutics, Inc. (FOLD), Wednesday announced that Japan's Ministry of Health, Labour and Welfare or MHLW has approved the combination therapy of Pombiliti and Opfolda for the treatment of adult patients with late-onset Pompe disease, an inherited lysosomal di - 2025-06-25 08:47:15
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Consensus PT from Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among brokers […] - 2025-06-17 03:08:53
Millennium Management LLC Has $4.31 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Millennium Management LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 10.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 457,014 shares of the biopharmaceutical company’s stock after buying an additional 44,449 shares during the period. Millennium Management LLC’s holdings in Amicus Therapeutics were worth $4,305,000 at the end […] - 2025-05-30 05:39:05
Implied ESGV Analyst Target Price: $116
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-26 08:27:28
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Man Group plc
Man Group plc lowered its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 92.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,441 shares of the biopharmaceutical company’s stock after selling 680,887 shares during the quarter. Man Group plc’s holdings in Amicus […] - 2025-05-26 04:59:00
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.22
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average […] - 2025-05-23 03:14:52
Nuveen Asset Management LLC Buys 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Nuveen Asset Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 4.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,807,420 shares of the biopharmaceutical company’s stock after buying an additional 159,139 shares during the quarter. Nuveen Asset Management […] - 2025-05-21 05:10:52
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by BNP Paribas Financial Markets
BNP Paribas Financial Markets decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 14.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 484,560 shares of the biopharmaceutical company’s stock after selling 81,416 […] - 2025-05-14 06:11:00
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Jane Street Group LLC
Jane Street Group LLC lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 324,270 shares of the biopharmaceutical company’s stock after purchasing an additional 23,524 shares during the period. Jane […] - 2025-05-14 05:24:55
The Manufacturers Life Insurance Company Decreases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
The Manufacturers Life Insurance Company cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 2.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,788 shares of the biopharmaceutical company’s stock after selling 4,214 shares during the quarter. The Manufacturers […] - 2025-05-13 05:27:02
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by StockNews.com
StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a buy rating to a hold rating in a research note released on Monday. A number of other equities research analysts have also recently commented on FOLD. Wells Fargo & Company reduced their target price on shares of Amicus Therapeutics from $18.00 to $17.00 […] - 2025-05-06 02:36:47
Amicus Therapeutics (NASDAQ:FOLD) Given New $22.00 Price Target at UBS Group
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price target lifted by UBS Group from $21.00 to $22.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” […] - 2025-05-05 04:25:01
CANADA LIFE ASSURANCE Co Has $753,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
CANADA LIFE ASSURANCE Co lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,076 shares of the biopharmaceutical company’s stock after acquiring an additional 5,522 […] - 2025-04-30 05:44:09
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Average Price Target from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […] - 2025-04-28 02:39:09
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legal & General Group Plc
Legal & General Group Plc decreased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 5.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 257,064 shares of the biopharmaceutical company’s stock after selling 15,329 shares during the quarter. […] - 2025-04-25 05:13:10
Implied VBK Analyst Target Price: $326
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-24 08:03:06
Russell Investments Group Ltd. Acquires 44,945 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Russell Investments Group Ltd. boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 539.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 53,282 shares of the biopharmaceutical company’s stock after acquiring an additional 44,945 shares during the quarter. Russell Investments Group Ltd.’s holdings in Amicus Therapeutics were worth $502,000 at […] - 2025-04-24 07:00:53
Alliancebernstein L.P. Sells 6,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Alliancebernstein L.P. lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 1.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 362,429 shares of the biopharmaceutical company’s stock after selling 6,800 shares during the period. Alliancebernstein L.P. owned 0.12% of […] - 2025-04-15 04:52:59
Orion Portfolio Solutions LLC Reduces Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
Orion Portfolio Solutions LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 8.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 84,693 shares of the biopharmaceutical company’s stock after selling 7,955 shares during the period. Orion Portfolio Solutions LLC’s holdings in Amicus Therapeutics were worth $798,000 as […] - 2025-04-07 05:34:53

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc FOLD holdings

DateNumber of FOLD Shares HeldBase Market Value of FOLD SharesLocal Market Value of FOLD SharesChange in FOLD Shares HeldChange in FOLD Base ValueCurrent Price per FOLD Share HeldPrevious Price per FOLD Share Held
2025-09-26 (Friday)21,690USD 178,726USD 178,726
2025-09-25 (Thursday)21,690USD 180,461FOLD holding decreased by -651USD 180,4610USD -651 USD 8.32001 USD 8.35002
2025-09-24 (Wednesday)21,690USD 181,112USD 181,112
2025-09-17 (Wednesday)21,550USD 171,754FOLD holding decreased by -862USD 171,7540USD -862 USD 7.97002 USD 8.01002
2025-09-16 (Tuesday)21,550USD 172,616USD 172,616
2025-09-12 (Friday)21,410USD 171,066USD 171,066
2025-09-11 (Thursday)21,410USD 171,708USD 171,708
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of FOLD by Blackrock for IE00B3VWM098

Show aggregate share trades of FOLD

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-70 7.600* 8.07 Profit of 565 on sale
2025-07-31BUY210 5.990* 8.09
2025-06-30SELL-140 5.730* 8.34 Profit of 1,168 on sale
2025-06-25SELL-70 5.660* 8.40 Profit of 588 on sale
2025-06-20SELL-140 5.640* 8.46 Profit of 1,184 on sale
2025-05-23BUY70 6.220* 8.85
2025-05-19SELL-70 6.420* 8.93 Profit of 625 on sale
2025-05-15SELL-210 5.950* 8.98 Profit of 1,886 on sale
2025-05-12SELL-70 6.210* 9.06 Profit of 634 on sale
2025-05-09SELL-70 5.980* 9.09 Profit of 636 on sale
2025-04-30SELL-70 7.680* 9.26 Profit of 648 on sale
2025-04-24SELL-140 7.200* 9.33 Profit of 1,307 on sale
2025-04-17SELL-70 6.830* 9.46 Profit of 662 on sale
2025-04-15SELL-210 6.900* 9.52 Profit of 1,999 on sale
2025-04-14SELL-210 6.720* 9.55 Profit of 2,005 on sale
2025-04-09SELL-280 6.890* 9.65 Profit of 2,701 on sale
2025-04-07SELL-497 7.150* 9.71 Profit of 4,826 on sale
2025-04-04SELL-710 7.500* 9.74 Profit of 6,913 on sale
2025-03-31BUY71 8.160* 9.80
2025-03-19SELL-142 9.200* 9.91 Profit of 1,407 on sale
2025-03-14SELL-426 8.900* 9.95 Profit of 4,237 on sale
2025-03-13SELL-142 8.810* 9.96 Profit of 1,415 on sale
2025-03-12SELL-2,414 8.890* 9.98 Profit of 24,083 on sale
2025-03-07SELL-142 8.860* 10.03 Profit of 1,424 on sale
2025-03-06SELL-213 9.020* 10.05 Profit of 2,140 on sale
2025-03-03SELL-71 9.130* 10.09 Profit of 716 on sale
2025-02-28SELL-426 9.490* 10.10 Profit of 4,302 on sale
2025-02-26SELL-71 9.030* 10.13 Profit of 719 on sale
2025-02-25SELL-213 9.110* 10.15 Profit of 2,162 on sale
2025-02-18BUY355 9.850* 10.23
2025-02-13BUY71 9.640* 10.26
2025-02-12BUY71 9.550* 10.27
2025-02-11BUY213 9.570* 10.29
2025-02-06BUY639 9.830* 10.33
2025-01-27BUY71 9.680* 10.47
2024-12-30BUY355 9.410* 10.59
2024-12-06BUY284 9.730* 10.66
2024-12-05BUY71 9.760* 10.69
2024-12-04BUY355 9.860* 10.72
2024-11-29BUY355 9.980* 10.82
2024-11-27BUY284 9.960* 10.89
2024-11-26BUY71 9.870* 10.94
2024-11-21BUY355 9.500* 11.14
2024-11-20BUY213 9.590* 11.23
2024-11-18BUY852 9.660* 11.44
2024-11-12BUY560 10.490* 11.50
2024-11-08BUY350 10.990* 11.54
2024-11-07BUY1,050 10.980* 11.58
2024-11-06BUY140 11.240* 11.61
2024-10-31BUY70 11.420* 11.66
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of FOLD

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-191,488,7631,8684,979,70929.9%
2025-09-18749,54323,429,70021.9%
2025-09-17397,55102,186,57318.2%
2025-09-161,266,28402,988,91242.4%
2025-09-15367,97001,408,96326.1%
2025-09-12462,4251,1001,133,39540.8%
2025-09-11290,1661620,50046.8%
2025-09-10431,29801,348,81532.0%
2025-09-09307,856350807,67138.1%
2025-09-08421,4121,7961,125,84137.4%
2025-09-05865,6714,0852,009,68543.1%
2025-09-041,184,15428,6211,615,93673.3%
2025-09-03616,2957,3061,255,99149.1%
2025-09-02549,2589,1001,751,69131.4%
2025-08-29689,01314,0941,505,85945.8%
2025-08-28721,01701,700,40242.4%
2025-08-27424,8710737,57157.6%
2025-08-26564,0615,264995,60756.7%
2025-08-25548,93014,7041,141,65848.1%
2025-08-22609,92001,139,96853.5%
2025-08-21626,6743,0001,014,02061.8%
2025-08-20388,5150695,98655.8%
2025-08-19445,1450771,27457.7%
2025-08-18738,47001,286,78657.4%
2025-08-15521,6691001,348,56038.7%
2025-08-14529,38901,758,49430.1%
2025-08-13971,64203,804,49525.5%
2025-08-12536,4591001,292,30841.5%
2025-08-11272,4798671,072,56025.4%
2025-08-08524,0121441,796,32429.2%
2025-08-07814,54901,804,45845.1%
2025-08-06954,5381,7301,610,85559.3%
2025-08-051,002,36901,936,40251.8%
2025-08-041,090,62502,883,31237.8%
2025-08-01787,17102,015,91939.0%
2025-07-31968,69303,885,03824.9%
2025-07-30734,81201,483,36849.5%
2025-07-29716,4781,0261,390,44351.5%
2025-07-28666,6158,6331,887,88235.3%
2025-07-25591,417301,568,56537.7%
2025-07-24539,25501,117,74048.2%
2025-07-23594,1653551,186,11450.1%
2025-07-22471,6723,2601,155,17240.8%
2025-07-21757,19718,5731,533,38149.4%
2025-07-18827,03201,740,06147.5%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.